Literature DB >> 25189089

The multi-site prescription opioid addiction treatment study: 18-month outcomes.

Jennifer Sharpe Potter1, Jessica A Dreifuss2, Elise N Marino3, Scott E Provost4, Dorian R Dodd4, Lindsay S Rice4, Garrett M Fitzmaurice5, Margaret L Griffin2, Roger D Weiss6.   

Abstract

Despite the high prevalence of prescription opioid dependence in the U.S., little is known about the course of this disorder and long-term response to treatment. We therefore examined 18-month post-randomization outcomes of participants in the Prescription Opioid Addiction Treatment Study, a multi-site, randomized controlled trial examining varying durations of buprenorphine-naloxone treatment and different intensities of counseling for prescription opioid dependence. Thus the current follow-up study provides a unique contribution to the field by reporting longer-term outcomes of a well-characterized population of treatment-seeking prescription opioid dependent patients. Participants from the treatment trial (N=252/653) completed an 18-month follow-up telephone assessment. Multivariable analyses examined associations between participant characteristics and key indicators of month-18 status: opioid abstinence, DSM-IV opioid dependence, and opioid agonist treatment. Overall, participants showed improvement from baseline to month 18: 49.6% were abstinent in the previous 30 days, with only 16.3% opioid-dependent. Some participants, however, had initiated past-year heroin use (n=9) or opioid injection (n=17). Most participants (65.9%) engaged in substance use disorder treatment during the past year, most commonly opioid agonist therapy (48.8%). Of particular interest in this population, multivariable analysis showed that greater pain severity at baseline was associated with opioid dependence at 18 months. In conclusion, although opioid use outcomes during the treatment trial were poor immediately following a buprenorphine-naloxone taper compared to those during 12 weeks of buprenorphine-naloxone stabilization, opioid use outcomes at 18-month follow-up showed substantial improvement over baseline and were comparable to the rate of successful outcomes during buprenorphine-naloxone stabilization in the treatment trial.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Clinical trial; Follow-up; Prescription opioids; Substance use disorder; Treatment

Mesh:

Substances:

Year:  2014        PMID: 25189089      PMCID: PMC4250351          DOI: 10.1016/j.jsat.2014.07.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  29 in total

1.  Alcoholics Anonymous attendance, decreases in impulsivity and drinking and psychosocial outcomes over 16 years: moderated-mediation from a developmental perspective.

Authors:  Daniel M Blonigen; Christine Timko; John W Finney; Bernice S Moos; Rudolf H Moos
Journal:  Addiction       Date:  2011-09-21       Impact factor: 6.526

2.  Do research payments precipitate drug use or coerce participation?

Authors:  David S Festinger; Douglas B Marlowe; Jason R Croft; Karen L Dugosh; Nicole K Mastro; Patricia A Lee; David S Dematteo; Nicholas S Patapis
Journal:  Drug Alcohol Depend       Date:  2005-01-23       Impact factor: 4.492

3.  Methods of detoxification and their role in treating patients with opioid dependence.

Authors:  Patrick G O'Connor
Journal:  JAMA       Date:  2005-08-24       Impact factor: 56.272

4.  A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): rationale, design, and methodology.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; Scott E Provost; Zhen Huang; Petra Jacobs; Albert Hasson; Robert Lindblad; Hilary Smith Connery; Kristi Prather; Walter Ling
Journal:  Contemp Clin Trials       Date:  2010-01-29       Impact factor: 2.226

5.  Conducting clinical research with prescription opioid dependence: defining the population.

Authors:  Roger D Weiss; Jennifer S Potter; Marc L Copersino; Kristi Prather; Petra Jacobs; Scott Provost; David Chim; Jeffrey Selzer; Walter Ling
Journal:  Am J Addict       Date:  2010 Mar-Apr

6.  A comparison of diagnoses obtained from in-person and telephone interviews, using the semi-structured assessment for the genetics of alcoholism (SSAGA).

Authors:  John R Kramer; Grace Chan; Samuel Kuperman; Kathleen K Bucholz; Howard J Edenberg; Marc A Schuckit; Linnea A Polgreen; Ellen S Kapp; Victor M Hesselbrock; John I Nurnberger; Laura J Bierut
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

7.  A method to diagnose opioid dependence resulting from heroin versus prescription opioids using the Composite International Diagnostic Interview.

Authors:  Jennifer S Potter; Kristi Prather; Frankie Kropp; Mimmie Byrne; C Rollynn Sullivan; Nadia Mohamedi; Marc L Copersino; Roger D Weiss
Journal:  Contemp Clin Trials       Date:  2010-01-14       Impact factor: 2.226

Review 8.  Buprenorphine for the management of opioid withdrawal.

Authors:  Linda Gowing; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  Combined pharmacotherapies and behavioral interventions for alcohol dependence (The COMBINE Study): examination of posttreatment drinking outcomes.

Authors:  Dennis M Donovan; Raymond F Anton; William R Miller; Richard Longabaugh; James D Hosking; Marston Youngblood
Journal:  J Stud Alcohol Drugs       Date:  2008-01       Impact factor: 2.582

10.  Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.

Authors:  Brent A Moore; David A Fiellin; Declan T Barry; Lynn E Sullivan; Marek C Chawarski; Patrick G O'Connor; Richard S Schottenfeld
Journal:  J Gen Intern Med       Date:  2007-04       Impact factor: 5.128

View more
  19 in total

1.  Effects of craving on opioid use are attenuated after pain coping counseling in adults with chronic pain and prescription opioid addiction.

Authors:  Bryan G Messina; Matthew J Worley
Journal:  J Consult Clin Psychol       Date:  2019-10

2.  Longitudinal association between pain severity and subsequent opioid use in prescription opioid dependent patients with chronic pain.

Authors:  Margaret L Griffin; Katherine A McDermott; R Kathryn McHugh; Garrett M Fitzmaurice; Robert N Jamison; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2016-04-25       Impact factor: 4.492

3.  Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study.

Authors:  Roger D Weiss; Jennifer Sharpe Potter; Margaret L Griffin; Scott E Provost; Garrett M Fitzmaurice; Katherine A McDermott; Emily N Srisarajivakul; Dorian R Dodd; Jessica A Dreifuss; R Kathryn McHugh; Kathleen M Carroll
Journal:  Drug Alcohol Depend       Date:  2015-03-06       Impact factor: 4.492

4.  Correlates of Opioid Abstinence in a 42-Month Posttreatment Naturalistic Follow-Up Study of Prescription Opioid Dependence.

Authors:  Roger D Weiss; Margaret L Griffin; David E Marcovitz; Blake T Hilton; Garrett M Fitzmaurice; R Kathryn McHugh; Kathleen M Carroll
Journal:  J Clin Psychiatry       Date:  2019-03-26       Impact factor: 4.384

5.  Characterizing pain and associated coping strategies in methadone and buprenorphine-maintained patients.

Authors:  Kelly E Dunn; Patrick H Finan; D Andrew Tompkins; Michael Fingerhood; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2015-10-19       Impact factor: 4.492

Review 6.  Prescription drug abuse: from epidemiology to public policy.

Authors:  R Kathryn McHugh; Suzanne Nielsen; Roger D Weiss
Journal:  J Subst Abuse Treat       Date:  2014-08-28

7.  Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Authors:  Arthur Robin Williams; Vincent Barbieri; Kaitlyn Mishlen; Frances R Levin; Edward V Nunes; John J Mariani; Adam Bisaga
Journal:  Am J Addict       Date:  2017-03-22

Review 8.  Prescription Opioid Misuse, Abuse, and Treatment in the United States: An Update.

Authors:  Kathleen T Brady; Jenna L McCauley; Sudie E Back
Journal:  Am J Psychiatry       Date:  2015-09-04       Impact factor: 18.112

9.  Treatment Trajectories During and After a Medication Trial for Opioid Use Disorder: Moving from Research as Usual to Treatment as Usual.

Authors:  Marc Fishman; Hoa T Vo; Rachael Burgower; Michael Ruggiero; John Rotrosen; Josh Lee; Edward Nunes
Journal:  J Addict Med       Date:  2020 Jul/Aug       Impact factor: 3.702

10.  Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder.

Authors:  Kelly R Peck; Taylor A Ochalek; Joanna M Streck; Gary J Badger; Stacey C Sigmon
Journal:  Pain Med       Date:  2021-05-21       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.